Clinical Trial Update: A Study of RC48-ADC in Subjects With Advanced Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 clinical trial evaluating RC48-ADC in subjects with advanced breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• RC48-ADC (Disitamab Vedotin)

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Advanced Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED